Evidence map›Paper›PMID 34432196›Full record

ArticleCardiovascular drugs and therapy2022

Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study.

Nicholas J Montarello, Kuljit Singh, Ajay Sinhal, Dennis T L Wong, Richard Alcock, Sharmalar Rajendran, Rustem Dautov, Peter Barlis, Sanjay Patel, Stefan M Nidorf and 8 more

Open access · bronzeAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Observational
  7. Review
  8. Review
  9. Tandem lesions associate with angiographic progression of coronary artery stenoses.International journal of cardiology. Heart & vasculature · 2024
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 1 country.

Nicholas J MontarelloDepartment of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia.
Kuljit SinghDepartment of Cardiology, Gold Coast University Hospital, Gold Coast, Australia.
Ajay SinhalFlinders Medical Centre, Flinders University, Adelaide, Australia.
Dennis T L WongVictorian Heart Institute, Monash University, Clayton, Australia.
Richard AlcockRoyal Perth Hospital, Perth, Australia.
Sharmalar RajendranLyell McEwin Hospital, Adelaide, Australia.
Rustem DautovThe Prince Charles Hospital, Brisbane, Australia.
Peter BarlisThe Northern Hospital, Melbourne, Australia.
Sanjay PatelRoyal Prince Alfred Hospital, Sydney, Australia.
Stefan M NidorfGenesisCare Western Australia, Perth, Australia.
Peter L ThompsonGenesisCare Western Australia, Perth, Australia.
Thalia SalagarasSouth Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia.
Julie ButtersVictorian Heart Institute, Monash University, Clayton, Australia.
Nitesh NerlekarVictorian Heart Institute, Monash University, Clayton, Australia.
Giuseppe Di GiovanniSouth Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia.
Juanita L OttawaySouth Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia.
Stephen J NichollsVictorian Heart Institute, Monash University, Clayton, Australia.
Peter J PsaltisDepartment of Cardiology, Central Adelaide Local Health Network, Adelaide, Australia. peter.psaltis@adelaide.edu.au.
South Australian Health and Medical Research Institute · AUMonash University · AUBaker Heart and Diabetes Institute · AUCentral Adelaide Local Health NetworkFlinders University · AUGold Coast Hospital · AULyell McEwin Hospital · AUNorthern Hospital · AUPrince Charles Hospital · AURoyal Perth Hospital · AURoyal Prince Alfred Hospital · AUSir Charles Gairdner Hospital · AUThe Heart Research Institute · AU

Funding

Endothelial SK3 Channel Modulation of EDHF is Estrogen RegulatedR00HL102056 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI LIN, MIKE T · 2012 to 2014
$686k
Endothelial SK3 Channel Modulation of EDHF is Estrogen RegulatedK99HL102056 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LIN, MIKE T · 2010 to 2011
$194k
CARDIOVASCULAR/RENAL MECHANISMS OF HYPERTENSIONF32HL010137 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI ALEXANDER, BARBARA T · 1999 to 2001
$80k
6 · The paper itself

Abstract

introductionRecurrent event rates after myocardial infarction (MI) remain unacceptably high, in part because of the continued growth and destabilization of residual coronary atherosclerotic plaques, which may occur despite lipid-lowering therapy. Inflammation is an important contributor to this ongoing risk. Recent studies have shown that the broad-acting anti-inflammatory agent, colchicine, may reduce adverse cardiovascular events in patients post-MI, although the mechanistic basis for this remains unclear. Advances in endovascular arterial wall imaging have allowed detailed characterization of the burden and compositional phenotype of coronary plaque, along with its natural history and responsiveness to treatment. One such example has been the use of optical coherence tomography (OCT) to demonstrate the plaque-stabilizing effects of statins on both fibrous cap thickness and the size of lipid pools within plaque.

methodsThe Phase 2, multi-centre, double-blind colchicine for coronary plaque modification in acute coronary syndrome (COCOMO-ACS) study will evaluate the effect of colchicine 0.5 mg daily on coronary plaque features using serial OCT imaging in patients following MI. Recruitment for the trial has been completed with 64 participants with non-ST elevation MI randomized 1:1 to colchicine or placebo in addition to guideline recommended therapies, including high-intensity statins. The primary endpoint is the effect of colchicine on the minimal fibrous cap thickness of non-culprit plaque over an 18-month period. The COCOMO-ACS study will determine whether addition of colchicine 0.5 mg daily to standard post-MI treatment has incremental benefits on high-risk features of coronary artery plaques. If confirmed, this will provide new mechanistic insights into how colchicine may confer clinical benefits in patients with atherosclerotic cardiovascular disease.

trial registrationANZCTR trial registration number: ACTRN12618000809235. Date of trial registration: 11th of May 2018.

Indexed as

ColchicineMyocardial InfarctionPlaque, AtheroscleroticAcute Coronary SyndromeClinical Trials, Phase II as TopicCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDouble-Blind MethodHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsMulticenter Studies as TopicPhenotypeTomography, Optical CoherenceColchicineHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsColchicineCoronary plaqueFibrous capInflammationOptical coherence tomography

Identifiers

PMID34432196
PMCPMC8384919
OpenAlexW3193932000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.